Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01634191 · ClinicalTrials.gov registry record · Phase 1
Effects of Age and Sex on the Pharmacokinetics of Apremilast in Healthy Adults
A Phase 1 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT01634191 is a Phase 1 study that has completed, run by Amgen. The registered enrollment target is 36 participants.
The verdict
NCT01634191, a Phase 1 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the effects of age and sex on the pharmacokinetics and safety of a single oral dose of 30 mg apremilast in healthy adults.
Interventions
- DRUG Apremilast
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2012-02-01 |
| Est. Completion | 2012-04-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01634191
The ClinicalTrials.gov registry entry for NCT01634191 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Apremilast is the first listed.
NCT01634191 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01634191 about?
NCT01634191 is a clinical study titled "Effects of Age and Sex on the Pharmacokinetics of Apremilast in Healthy Adults". The purpose of the study is to evaluate the effects of age and sex on the pharmacokinetics and safety of a single oral dose of 30 mg apremilast in healthy adults.
What is the current status of trial NCT01634191?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2012-02-01. Estimated completion is 2012-04-01.
What interventions are being tested in trial NCT01634191?
The interventions under investigation include: Apremilast (DRUG).
Who is sponsoring clinical trial NCT01634191?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.